Acumen research and consulting estimates that the global immunosuppressants market is anticipated to reach market size of around US$ 45,000 Mn by 2027 and is anticipated to grow at a CAGR of around 14% in terms of revenue during the forecast period 2020 – 2027.
The immune reaction or agents during transplantation or grafting operations is removed by immunosuppressants. The body of the receiver develops certain immune response during the organ transplantation as it finds the tissue to be a toxic antigen for the host. These immunosuppressants contribute to the body's immune cell response. Such drugs are a key part of organ transplantation, as they prevent serious damage to the body.
The major driving force behind demand rise is the growing prevalence of autoimmune diseases like Asthma, MS and alopecia areata. However, the increase in the occurrence of organ failure in organ transplantation processes, such as renal transplants and liver transplants, further promotes market demand. For instance, in 2018 as per the U.S. Government Information on Organ Donation and Transplantation 36,528 organs were transplanted. There are limitations to development in this market that are lacking in the accessibility of organ donors and high transplantation rates, as well as in immunosuppressive medications. In fact, the demand growth is projected to be affected by the side effects of these drugs. One of the main side effects of these drugs is osteoporosis, in particular corticoids. The density of the bones is reduced and the chance of fractures is decreased. Each bone in the body may be damaged, but fractures in the leg, spine or wrist are more commonly seen. Instead, the growing use of tissue engineering to generate implants provides this market with development opportunities. Moreover, an increase in disposable income in developed countries is expected to generate attractive incentives for people to become aware of organ donation.
The market research study on “Immunosuppressants Market (By Drug Class: Corticosteroids, Monoclonal Antibodies (mAbs), Calcineurin Inhibitors, mTOR Inhibitors, Anti-Proliferative Agents, Others; By Indication: Organ Transplantation, Autoimmune Disorders, Non-Autoimmune Inflammatory Diseases; By Route of Administration: Oral, Parenteral; By Distribution Channel: Hospital pharmacies, Retail pharmacies, Online pharmacies) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2020 - 2027” offers detailed insights on the global immunosuppressants market entailing insights on its different market segments. Market dynamics with drivers, restraints and opportunities with their impact are provided in the report. The report also provides competitive landscape to understand the current stance of particular player. The report provides insights on global immunosuppressants market are offering energy type, services, end-user, and major geographic regions. The immunosuppressants market analysis is provided for major regional markets including North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. For each region, the market size for different segments has been covered under the scope of report.
North America immunosuppressant market account for a significant share of global immunosuppressant markets attributed for an expansion in auto-immune disease prevalence and drug launches throughout the U.S. For instance, according to the American Autoimmune Related Disease Association in 2018, approximately 55 Mn people were suffering from the autoimmune diseases. The European market in immunosuppressant drugs is projected to expand significantly due to the current growth in the rate of organ transplantation develop new medicines, and improved health services in the region. For instance, in 2018, according to European Commission xx organ transplantation cases has observed in Europe. However, Asia Pacific is an developing region for the immunosuppressants market, is projected to boost the demand due to increased medical tourism due to low medical costs, the launch of newer drugs and an rise in the incidence of autoimmune diseases.
A major player included in this report such as Novartis AG, Bristol Myers Squibb, Zydus, GlaxoSmithKline Plc., Astellas Pharma, Inc., Johnson & Johnson, F. Hoffmann La Roche Ltd., Mylan Laboratories Inc., Pfizer, Inc., Intas Pharmaceuticals Ltd., Sanofi S.A, and others. The global market for immunosupressants drugs is extremely competitive, and leading companies have used varied approaches to expand footprints, such as new product launch, growth, collaborations, joint projects, partnerships, acquisitions and others.
The global immunosuppressants market is segmented as below:
Market By Drug Class
Market By Indication
Market By Distribution Channel
Market By Route of Administration
Market By Geography
Middle East & Africa
The immune reaction or agents during transplantation or grafting operations is removed by immunosuppressants. The body of the receiver develops certain immune response during the organ transplantation as it finds the tissue to be a toxic antigen for the host.
According to Acumen Research and Consulting, the immunosuppressants market value is anticipated to be hit around US$ 45,000 Mn in 2027.
The immunosuppressants market is anticipated to grow around 14% CAGR amid the forecast period 2020-2027.
Strict regulatory policies and compliances associated with the approval of drugs is a factor that may hamper the growth of the market.
Higher prevalence of autoimmune disorders and greater population base requiring effective therapies for these diseases is the major drivers for the growth of the immunosuppressants market.
A major player included in this immunosuppressants market report such as Novartis AG, Bristol Myers Squibb, Zydus, GlaxoSmithKline Plc., Astellas Pharma, Inc., Johnson & Johnson, F. Hoffmann La Roche Ltd., Mylan Laboratories Inc., Pfizer, Inc., Intas Pharmaceuticals Ltd., Sanofi S.A, and others.
North America immunosuppressant market account for a significant share of global immunosuppressant markets attributed for an expansion in auto-immune disease prevalence and drug launches throughout the U.S.